UNSPSC 51111846: Epitiostanol

This classification denotes a therapeutic androgen and anabolic steroid with the molecular formula C19H30OS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier YE7586973L, chemically known as 2,3-epithioandrostan-17-ol but generally known as epitiostanol, which bears US NIH Compound Identifier 3243. European Medicines Agency schedules Epitiostanol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06572MIG.

UNSPSC 51111846 Epitiostanol is a Commodity code representing individual pharmaceutical products supplied through state and local government cooperative purchasing vehicles. State and local governments buy epitiostanol and similar generic pharmaceuticals through multi-source contracts that establish pricing and supply agreements with manufacturers, who then distribute through authorized wholesalers to participating healthcare facilities, correctional systems, and other public agencies. The issuing bodies are primarily state health departments and multistate cooperative purchasing alliances administering contracts on behalf of multiple member agencies—counties, cities, and special districts that lack independent procurement capacity or leverage to negotiate directly with manufacturers.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP (S1070000015802) on January 20, 2026 for generic multi-source pharmaceuticals and OTC products with a response deadline of March 26, 2026. The contract covers participants across Minnesota and Oregon and requires vendors to maintain relationships with at least two of three authorized wholesalers (AmerisourceBergen Drug Corporation / Cencora, Cardinal Health 110 and 112, Morris & Dickson Co., LLC), comply with cGMP and the Drug Supply Chain Security Act, and submit detailed product information including NDC codes, UPCs, strength, dosage form, and manufacturing location. Evaluation weights 75 percent price competitiveness, with the remaining 25 percent split among fixed pricing, administrative fee compliance, EDI capability, and pricing format flexibility. The contract runs two years for new vendors with optional extensions, with awarded vendors effective July 1, 2026, and subject to a 3 percent administrative fee on all purchases plus performance penalties up to $1,500 per violation.